Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still BuysThe Motley Fool • 07/03/23
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million UpfrontSeeking Alpha • 07/02/23
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1Business Wire • 06/29/23
This Sentiment Gauge Just Reached Its Most Optimistic Level Since Pre-Covid Days. Time to Buy Stocks?The Motley Fool • 06/29/23
Dow Jones Drug Giant Merck Eyes Buy Point; 3 Other Leaders To Buy Or WatchInvestors Business Daily • 06/26/23
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USAGlobeNewsWire • 06/22/23
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaBusiness Wire • 06/20/23
Merck: Approaching The Accumulation Phase With An Expanding Product PortfolioSeeking Alpha • 06/17/23
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaBusiness Wire • 06/16/23